Overview
Suven Life Sciences Limited is a clinical-stage biopharmaceutical company primarily focused on developing novel therapeutics for neurodegenerative disorders. Its operations include Contract Research And Manufacturing Services (CRAMS), offering process research, clinical trial supplies, and exclusive manufacturing services.
The company has expanded its drug discovery into areas such as Major Depressive Disorder, pain management, and obesity, showcasing its specialization in CNS-based programmes.
Suven's subsidiary, Suven Neurosciences, Inc., USA, is dedicated to advancing clinical studies of Suven molecules, indicating significant investments in international operations related to CNS therapies.
In FY15, Suven entered into an exclusive licensing agreement with Taro Pharmaceuticals for its Malathion lotion, expected to yield revenue and royalties from the US, Canada, and Mexico markets.
Several new molecules have been added to Suven's drug pipeline, with significant investments in R&D and clinical trials, reinforcing their commitment to addressing niche medical needs.
- Sector
Healthcare Services
- Industry
Healthcare Research, Analytics & Technology
- Market Cap
5,728 Cr
- Volatility
Moderate Risk
- P/E Ratio
-20.9
- Industry P/E
56.4
- PEG Ratio
—
- P/B Ratio
7.5
- 52W High
303.00
- 52W Low
118.55
Financial Ratios
Sales CAGR
- 1Y
- -43.03%
- 3Y
- -17.48%
- 5Y
- -14.32%
- 10Y
- -38.12%
Profit CAGR
- 1Y
- -52.98%
- 3Y
- —
- 5Y
- —
- 10Y
- —
ROE
- TTM
- -75.33%
- 3Y
- -50.85%
- 5Y
- -60.26%
- 10Y
- -12.27%
ROCE
- TTM
- -75.33%
- 3Y
- -50.55%
- 5Y
- -59.88%
- 10Y
- -7.21%
Forecasts
Peers
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
167.10 | 5,728 Cr | -20.85 | 7.47 | 0.00 | -75.33 | -75.33 | -81.41 | ||
408.05 | 2,138 Cr | 34.83 | 6.24 | 0.21 | 14.59 | 19.04 | 13.94 | ||
46.04 | 641 Cr | 398.23 | 24.85 | 0.00 | 15.55 | 21.32 | 4.57 | ||
64.02 | 158 Cr | -51.37 | 2.48 | 0.00 | -9.29 | -5.26 | -2.47 | ||
57.69 | 144 Cr | -12.50 | 0.32 | 0.00 | -2.81 | 0.93 | -2.96 | ||
17.03 | 82 Cr | 328.72 | 1.51 | 0.00 | 1.03 | 3.26 | 0.36 | ||
50.29 | 59 Cr | -27.02 | 3.24 | 0.00 | -30.18 | -32.45 | -30.18 | ||
| Median: 7 Co. | — | 57.69 | 158 Cr | -12.50 | 3.24 | 0.00 | -2.81 | 0.93 | -2.47 |
Price Chart Comparison
Documents
Investor Presentation
Q1 FY22
Investor Presentation
Q2 FY20
Investor Presentation
Q1 FY20
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY19
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY19
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY19
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY19
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY19
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Actions
AI Mode
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Ask AI
